As depicted in Fig. 5A, only the combination treatment was efficient in inhibiting the tumor growth, suggesting that, whereas responses in patients with a PIK3CA preexisting mutation are possible, the PIK3CA E545K mutation contributes to the oncogenic signaling and its targeting seems relevant to maximize tumor response. This evidence concerns the gene PIK3CA and neoplasm.